Peripheral sensory neuropathy and cisplatin chemotherapy

Area of Science:

• Oncology
• Neuroscience
• Pharmacology

Background:

• Advanced cancer treatment often involves combination chemotherapy.
• Cisplatin and Adriamycin are commonly used chemotherapeutic agents.
• Peripheral neuropathy is a known side effect of certain chemotherapy drugs.

Purpose of the Study:

• To evaluate the incidence and characteristics of peripheral neuropathy in previously untreated advanced cancer patients receiving cisplatin and Adriamycin.
• To investigate the neurological and electrophysiological changes associated with this treatment regimen.

Main Methods:

• Monthly intravenous administration of cisplatin (60 mg/m2) and Adriamycin (60 mg/m2) to patients with advanced cancer.
• Clinical assessment of neurological signs and symptoms, including sensory and reflex changes.
• Electrophysiological studies measuring nerve conduction velocities and latencies.
• Sural nerve biopsies to examine nerve fiber morphology.

Main Results:

• Peripheral neuropathy, predominantly sensory, occurred in 92% of patients.
• Common symptoms included dysesthesias and paresthesias in extremities.
• Clinical findings revealed decreased tendon reflexes, impaired vibratory sense, and reduced light touch/pin sensation.
• Nerve conduction studies showed prolonged or absent distal sensory latencies with minimal motor changes.
• Sural nerve biopsies indicated loss of large nerve fibers with axonal and myelin degeneration.

Conclusions:

• Combination chemotherapy with cisplatin and Adriamycin is associated with a high incidence of sensory peripheral neuropathy in advanced cancer patients.
• The neuropathy is characterized by sensory nerve fiber damage.
• Further research is warranted to explore neuroprotective strategies during chemotherapy.